Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$1.18
$0.01(0.85%)
At close: 4:00 PM EDT
$1.18
$0.01(0.85%)
Day’s Range― - ―
52-Week Range$0.89 - $13.48
Previous Close$0.36
Volume124.96K
Average Volume (3M)125.69K
Market Cap
$21.32M
Enterprise Value$32.75
Total Cash (Recent Filing)$1.89M
Total Debt (Recent Filing)$8.51M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding17,477,144
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)$4.69M
Bulls Say, Bears Say
Bulls Say
CDMO / Manufacturing Services Revenue StreamThe CDMO business creates a fee-based, non-binary revenue channel distinct from product commercialization. Contract manufacturing can produce recurring service revenue, improve utilization of existing assets, and partially offset R&D burn, supporting liquidity and operational scale over the medium term.
Middle East Commercialization Partnership (Amarox)The Amarox agreement establishes a tangible commercial pathway and local regulatory partner in a major regional market. This structural partnership can accelerate market access, de-risk launch logistics, and create a replicable regional commercialization model if approvals and execution proceed as planned.
Peer-reviewed Phase 3 Manuscript AcceptanceAcceptance in a respected journal strengthens scientific validation of Multikine’s Phase 3 findings. Peer-reviewed publication can support regulatory submissions, increase clinician awareness, and improve credibility with partners and payors, aiding long-term approval and adoption prospects.
Bears Say
No Product Revenue; Persistent Operating LossesAs a pre-commercial biotech with no product revenue and sustained multi-year losses, Cel-Sci remains dependent on external financing. Persistent negative profitability limits reinvestment ability, raises dilution risk, and constrains long-term growth unless a clear commercial ramp materializes.
Consistent Negative Operating And Free Cash Flow (cash Burn)Sustained operating cash burn of roughly $16–23M per year creates runway pressure absent material service revenue or financing. Continued negative cash generation risks forced financing, which can be dilutive and may limit the company’s ability to fund confirmatory trials or build commercial infrastructure.
TTM Balance-sheet Scale Shift And Comparability RiskA marked TTM shift in assets and debt versus annual filings signals structural changes that complicate trend analysis and financing planning. Combined with negative returns on equity, this amplifies uncertainty about capital structure, covenant risk, and the firm's ability to finance commercialization without adverse terms.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $0.89 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $21.32M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 16 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on May 18, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 17,477,144 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20.28%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Technical Analysis
Ownership Overview
3.17% Insiders
1.84% Mutual Funds
0.06% Other Institutional Investors
91.78% Public Companies and
Individual Investors